ClinicalTrials.gg
RecruitingNCT05738096Updated Nov 3, 2026

Trigeminal Evoked Responses to Improve Rhizotomy

An Early Phase 1 interventional study of TSEP + rhizotomy surgery and TSEPs recording only in Trigeminal Neuralgia and Rhizotomy, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Minnesota · Early Phase 1, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.

Planned enrollment
11th of 26
30 · median 29
Started
2023
the only one that year
Phase 1
5 of 34
2 open now
Primary completion
2027-11
later than 6 of 10 live
Registered
31st of 34
by date
Lead sponsor
3 of 34
University of Minnesota

Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is the 11th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 1, reaches primary completion later than 6 of the 10 other live ones, and was the 31st registered.

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

Browse Trigeminal Neuralgia studies →

Open to participants now

7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Trigeminal Neuralgia with a site in United States, or all of them as a file.
02

Study summary

Trigeminal neuralgia (TGN) is a debilitating pain syndrome where electrical, shock- like jolts of pain affect the face. Trigeminal somatosensory evoked potentials (TSEPs) provide a promising modality for measuring the trigeminal sensory and nociceptive pathway by using peripheral stimulation of the trigeminal nerve (on the skin) and measuring low latency evoked potentials on the scalp (contralateral sensory cortex). While TSEPs have been measured in the past, it is not clear if implementing TSEPs into a routine neurosurgical rhizotomy procedure will be feasible. This is a prospective cohort study examining the feasibility of routinely performing TSEPs during rhizotomies for TGN.

03

Conditions studied

  • Trigeminal Neuralgia
  • Rhizotomy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults of 18 years or older
  • Scheduled to undergo percutaneous rhizotomy for facial pain

Exclusion criteria

Exclusion Criteria:

  • For TGN: Facial pain of unclear origin (i.e. not clearly TGN pain) or Rhizotomy procedure canceled
  • For Healthy control: Diagnosis or history of facial pain such as TMD or TGN, History of migraine, History of any functional pain disorder: fibromyalgia, IBS, CRPS or Recent chronic pain (within last month)
05

Study design

Phase
Early Phase 1
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    TGN patients

    Patients with TGN who will undergo rhizotomy surgery as the standard of care

    Other: TSEP + rhizotomy surgery

  • Active comparator
    Healthy volunteers

    Healthy volunteers for whom TSEPS will be recorded in a lab setting

    Other: TSEPs recording only

Interventions

  • OtherTSEP + rhizotomy surgery

    TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery. TSEPs will be measured at baseline prior to surgery. During the rhizotomy procedure, an electrode or balloon is placed through a metal sheath to then damage the nerve. A stylet is introduced to clear tissue from the sheath in preparation for the electrode or balloon. Prior to the final insertion of the RF electrode where the gasserian ganglion will be damaged, we will place a standard stereotactic EEG electrode (SEEG). Following damaging the nerve (clinical procedure), we will record again to measure differences in the TSEPs following cell body damage. The Neuralynx system will be used to record the potentials at 40 KHz.

  • OtherTSEPs recording only

    TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.

06

What researchers measure

Primary outcomes

  1. Feasibility

    total study procedure completion rate

    Time frame: 3 years

Secondary outcomes

  1. TSEPS peak to peak amplitude within TGN

    difference in measured peak to peak amplitude between normal and TGN side

    Time frame: 1 day

  2. TSEPS latency within TGN

    difference in measured TSEPS latency between normal and TGN side

    Time frame: 1 day

  3. TSEPS peak to peak amplitude between control and TGN patients

    difference in measured peak to peak amplitude between healthy participants and TGN patients

    Time frame: 1 day

  4. TSEPS latency between control and TGN patients

    difference in latency between healthy participants and TGN patients

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Nov 2026 → Nov 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Feb 21, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Nov 1, 2027was Nov 2026
CompletionEst.
Nov 1, 2027was Nov 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2026→Nov 1, 2027
Nov 3, 2026
Study completion
Nov 1, 2026→Nov 1, 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Nov 1, 2026→Nov 1, 2027
    Study completion Nov 1, 2026→Nov 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05738096
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Nov 1, 2023
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Matthew Maple
Contact
maple036@umn.edu
612-626-3582
David P Darrow, MD
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion